by The Journal of Clinical Psychopharmacology
A podcast detailing current topics in the Journal of Clinical Psychopharmacology.
Language
🇺🇲
Publishing Since
4/22/2021
Email Addresses
1 available
Phone Numbers
0 available
March 4, 2025
<p>"Designer benzodiazepines" are lab-created chemical derivatives of prescription benzodiazepines. They have not been approved for medical use and there is limited information on their safety and toxicity. More potent than their prescription counterparts, this subset of novel psychoactive substances have been growing in popularity in recent years and pose the potential for dangerous levels of intoxication.</p> <p>In this podcast, Dr. Sahil Munjal, program director of the Atrium Health Wake Forest Baptist psychiatry residency program, leads a discussion of the article <a href= "https://doi.org/10.1097/JCP.0000000000001963">“Clinical Management of Designer Benzodiazepine Intoxication: A Systematic Review,"</a> with his coauthors Dr. Gregory Noe, Katelyn Li, and Nicholas McDuffee. They provide an overview of designer benzodiazepines in comparison to prescription benzodiazepines and describe the findings from their review of 35 case reports. They discuss clinical presentations of designer benzodiazepine intoxication, common approaches to clinical management, and key takeaways from their review of the literature. Their article appears <a href= "https://journals.lww.com/psychopharmacology/toc/2025/03000">in the March-April 2025 issue of The Journal of Clinical Psychopharmacology</a>.</p>
March 4, 2025
<p>Dr. Donald C. Goff, Marvin Stern professor of psychiatry at NYU Grossman School of Medicine, gives an overview of a new combination drug recently approved by the U.S. Food and Drug Administration for the treatment of schizophrenia. It will be marketed as Cobenfy, and its component active ingredients are xanomeline and trospium chloride, representing the first non-dopaminergic antipsychotic approved by the FDA. Dr. Goff briefly explores the decades of pharmaceutical treatment of schizophrenia and lays out the steps toward developing the new combination drug. He offers details on next steps, treatment, more extensive trials of the new drug, related approaches, and refers listeners to his editorial for prescribing information.</p> <p>His guest editorial, <a href= "https://doi.org/10.1097/JCP.0000000000001959">“At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy),”</a> is published in <a href= "https://journals.lww.com/psychopharmacology/toc/2025/03000">the March-April 2025 issue of The Journal of Clinical Psychopharmacology</a>.</p>
March 4, 2025
<p>Valproic acid is one of the most frequently prescribed mood-stabilizing agents for bipolar disorder, and in some regions of the world, it now competes with lithium as the preferred treatment of choice for bipolar maintenance. There may soon be restrictions on the use of valproic acid, however, because of the risk in neural tube defects and major congenital malformations in children born to mothers and fathers who take it.</p> <p>In this podcast, Dr. Samuel Dotson, from the Northeast Georgia Health System in Gainesville, Georgia, and Emory University in Atlanta, and Dr. Andrew Nierenberg, from the Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital and Harvard Medical School, discuss the current state of research regarding the benefits and risks of valproic acid in comparison to lithium use. They also discuss the importance of informing patients about their options, noting that lithium use has sometimes been perceived as riskier than it is. Dr. Dotson and Dr. Nierenberg are the authors of a Guest Editorial titled <a href= "https://doi.og/10.1097/JCP.0000000000001948">“Growing Concerns Over Valproate Teratogenicity Present an Opportunity for Lithium”</a> in <a href= "https://journals.lww.com/psychopharmacology/toc/2025/03000">the March-April 2025 issue of The Journal of Clinical Psychopharmacology</a>.</p>
Psychopharmacology Institute
Neuroscience Education Institute
Pocket Psychiatry: A Carlat Podcast
PsychEd
Mark Mullen, MD
David Puder, M.D.
John Bellone & Ryan Van Patten - NavNeuro
Gabe Howard
Dr. Dawn-Elise Snipes
Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist
ADDitude
Hidden Brain, Shankar Vedantam
The Curbsiders Internal Medicine Podcast
NPR
The New York Times
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.